1 / 19

Management of Heavy Menstrual Bleeding

Dr Sana’a Sabri GP ST1 14/12/2010. Management of Heavy Menstrual Bleeding. Learning Objectives. 1. Increased awareness of menorrhagia and its impact on individuals and the community 2. Increased confidence in ordering appropriate investigations

yoshi-acosta
Télécharger la présentation

Management of Heavy Menstrual Bleeding

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dr Sana’a Sabri GP ST1 14/12/2010 Management of Heavy Menstrual Bleeding

  2. Learning Objectives 1. Increased awareness of menorrhagia and its impact on individuals and the community 2. Increased confidence in ordering appropriate investigations 3. Knowledge of when to refer appropriately 4. Increased awareness of pharmacological treatments 5. Increased confidence in your ability to manage patients with menorrhagia

  3. What is heavy menstrual bleeding? (HMB) is excessive menstrual blood loss which interferes with a woman’s physical, social, emotional and/or material quality of life. It can occur alone or in combination with other symptoms. Is not associated with significant mortality and may be considered unimportant by some HCP Many women with HMB consult HCP in primary care and it is a common reason for referral to a specialist

  4. Heavy Menstrual Bleeding Treatment and care should take into account the woman’s needs and preferences Women with HMB should have the opportunity to make informed decisions about their care and treatment, in partnership with their HCP Good communication between HCP and women is essential

  5. Menorrhagia has a substantial impact on many women's lives: 1 in 20 women aged 30-49 years consults her GP each year with menorrhagia Once a woman has been referred to a gynaecologist, surgical intervention is highly likely 1 in 5 women in the UK will have a hysterectomy before age 60 years In 50-70% of women who undergo hysterectomy, menorrhagia is the main presenting problem, 50% have normal uterus Each year, around £7 million is spent in the UK on primary care prescriptions to treat menorrhagia

  6. Taking History Nature of the bleeding, related symptoms that might suggest structural or histological abnormality, impact on quality of life and other factors that may determine treatment options The presence of comorbidity The range and natural variability in menstrual cycles and blood loss If the history suggests HMB without structural or histological abnormality, pharmaceutical treatment can be started without carrying out a physical examination or other investigations at initial consultation in primary care

  7. Examination A physical examination should be carried out before all: LNG-IUS fittings (Mirena) Investigations for structural abnormalities Investigations for histological abnormalities Women with fibroids that are palpable abdominally or who have intracavity fibroids and/or whose uterine length as measured at ultrasound or hysteroscopy is greater than 12 cm should be offered immediate referral to a specialist

  8. Laboratory Tests FBC should be carried out on all women with HMB. This should be done in parallel with any HMB treatment offered. Testing for coagulation disorders A serum ferritin test Female hormone testing Thyroid testing

  9. Structural and histological investigations If appropriate, a biopsy should be taken to exclude endometrial cancer or atypical hyperplasia. Indications for a biopsy include, for example, persistent intermenstrual bleeding, and in women aged 45 and over treatment failure or ineffective treatment Imaging should be undertaken in the following circumstances: The uterus is palpable abdominally. Vaginal examination reveals a pelvic mass of uncertain origin. Pharmaceutical treatment fails.

  10. Investigations Ultrasound is the first-line diagnostic tool for identifying structural abnormalities. Hysteroscopy should be used as a diagnostic tool only when ultrasound results are inconclusive, for example, to determine the exact location of a fibroid or the exact nature of the abnormality Saline infusion sonography should not be used as a first-line diagnostic tool MRI should not be used as a first- line diagnostic tool Dilatation and curettage alone should not be used as a diagnostic tool

  11. Education & Information Provision A woman with HMB referred to specialist care should be given information before her outpatient appointment The Institute’s information for patients (‘Understanding NICE guidance’) is available from www.nice.org.uk/CG044publicinfo A woman with HMB should be given the opportunity to review and agree any treatment decision She should have adequate time and support from HCP in the decision-making process

  12. Treatment Options Medical: Pharmaceutical treatments for HMB Surgical Non-hysterectomy surgery for HMB Further interventions for uterine fibroids associated with HMB Hysterectomy

  13. Medical OptionThe treatments should be considered in the following order: a) Levonorgestrel-releasing intrauterine system (LNG-IUS) provided long-term (at least 12 months) use is anticipated b) Tranexamic acid or NSAIDs or COCs c) Norethisterone (15 mg) daily from days 5 to 26 of the menstrual cycle, or injected long-acting progestogens. (GnRH Analogues, Danazol, Luteal phase progestogenes, Etamsylate)‏

  14. Surgical OptionNon-Hysterectomy Endometrial Ablation (EA) Bleeding is having a severe impact on a woman’s quality of life, and she does not want to conceive in the future May be offered as an initial treatment for HMB after full discussion with the woman of the risks and benefits and of other treatment options Women must be advised to avoid subsequent pregnancy and on the need to use effective contraception, if required, after EA (Impedance-controlled bipolar radiofrequency A, Fluid-filled thermal balloon EA, Microwave EA)

  15. Further interventions for uterine fibroids associated with HMB For women with large fibroids and HMB, and symptomatic: dysmenorrhoea or pressure symptoms, referral for consideration of myomectomy or uterine artery embolisation (UAE) as first-line treatment can be recommended Women should be informed that UAE or myomectomy may potentially allow them to retain their fertility

  16. HysterectomyIndications: • Other treatment options have failed, are CI or are declined by the woman • There is a wish for amenorrhoea • The woman (who has been fully informed) requests it • The woman no longer wishes to retain her uterus and fertility Route: • presence of other gynaecological conditions or disease • uterine size • presence and size of uterine fibroids • mobility and descent of the uterus • size and shape of the vagina • history of previous surgery

  17. Recommedations for Referral for suspected CA Alterations in the menstrual cycle, IMB, PCB, PMB or vaginal discharge. The primary HCP should undertake a full pelvic examination, including speculum examination of the cervix O/E clinical features that raise the suspicion of cervical CA, an urgent referral should be made. A cervical smear is not required before referral, and a previous -ve smear result is not a reason to delay referral Palpable abdominal or pelvic mass O/E that is not obviously uterine fibroids or not of GI or urological origin should have an urgent USS. If the scan is suggestive of CA, or if USS is not available, an urgent referral should be made

  18. Doctors.net /E.learning module (Managing Mennorhagia) NICE Guidelines Jan 2007 (HMB)‏ NICE Guidelines Jun 2005 ( Referral Guidelines for Suspected CA)‏

  19. Thank you

More Related